US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
RSS Feeds

Biotechnology Industry Research & Market Reports

1  2    4    6  7  8  9  10  
Alkermes Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... understand Alkermes and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The ...  |  read more...
USD 1,495
Amgen Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making ...  |  read more...
USD 1,495
Biogen Idec Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and ...  |  read more...
USD 1,495
Mesenchymal Stem Cells - Advances & Applications
7/1/2015 | published by: BioInformant Worldwide, L.L.C.
... knowledge necessary to make informed, educated decisions about opportunities for commercialization within the rapidly-evolving mesenchymal stem cell (MSC) marketplace. It is produced for: Management of Stem Cell Product Companies Management of Stem Cell Therapy Companies ...  |  read more...
USD 6,495
Dendreon Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... understand Dendreon and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The ...  |  read more...
USD 1,495
Genentech Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making ...  |  read more...
USD 1,495
Conference Documentation: BioBanking
6/23/2015 | published by: SMI Publishing, Ltd
... specimen collections and repositories to ensure preservation of the integrity and future value of specimens, as well as practical implementation issues relating to privacy and confidentiality of research participants, this is a crucial time for ...  |  read more...
USD 788.78
Conference Documentation: Lyophilisation -Europe
6/30/2015 | published by: SMI Publishing, Ltd
... of biological products, and an invaluable tool for prolonging shelf life and stability for biological drugs and vaccines. As under met needs in drug transport and long term storage continues to prevail, robust lyophilisation methods ...  |  read more...
USD 788.78
Failure Analysis Market by Equipment (SEM, TEM, FIB, Dual), Technology (SIMS, EDX, CMP, FIB, BIM, RIE), Application (Material Science, Bio Science, Industrial & Electronics), Geography - Forecast to 2020
6/24/2015 | published by: MarketsandMarkets
... process being implemented across a wide range of sectors. This process is carried out using the failure analysis equipment devices mainly SEM, TEM, FIB, and dual-beam system and implementation of such devices varies from industry ...  |  read more...
USD 4,650
Trends in mammalian cell cultures
6/29/2015 | published by: Frost & Sullivan
... host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics. However, due to issues with low yields, poor quality and high costs, novel ...  |  read more...
USD 6,500
Vital Signs - The Analyst's Perspective - May 2015 Issue
6/30/2015 | published by: Frost & Sullivan
... Recent news published in the Annals of Internal Medicine reported that a new class of lipid lowering drugs is effective in lowering lipid levels in patients who are resistant to the already available lipid lowering ...  |  read more...
USD 450
Genmab Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... understand Genmab and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The ...  |  read more...
USD 1,495
Genzyme Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making ...  |  read more...
USD 1,495
Intermune Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... understand Intermune and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The ...  |  read more...
USD 1,495
Nektar Therapeutics Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... better understand Nektar Therapeutics and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company ...  |  read more...
USD 1,495
Novartis Partnering 2010-2015
7/1/2015 | published by: Current Partnering
... Novartis and its partnering interests and activities over the past five years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data. The report ...  |  read more...
USD 1,495
Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review
6/23/2015 | published by: GlobalData
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ...  |  read more...
USD 125
XOMA Corporation (XOMA) - Financial and Strategic SWOT Analysis Review
6/16/2015 | published by: GlobalData
... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ...  |  read more...
USD 125
Future Horizons and Growth Strategies in the German Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next ten years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the Spanish Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the German Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the Japanese Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 4,850
Expression Vectors Market by Host Type (Bacterial/E.Coli, Mammalian/CHO, Insect/Baculovirus, and Yeast), Application (Therapeutic, Research, and Industrial), End User (Pharmaceutical, Biotechnology, CROs & CMOs, and Academic Research) - Forecast to 2020
6/16/2015 | published by: MarketsandMarkets
... is expected to reach $317.1 million by 2020 from $242.7 million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. The market is categorized on the basis of host type, application, end ...  |  read more...
USD 4,650
Biologicals in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... developing 2333 biological drugs in 5702 developmental projects in cancer. In addition, there are 27 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1017 drugs. Biologicals In ...  |  read more...
USD 11,025
Fierce 15 in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... this award are aiming at breakthroughs and big things, not at being 'me-too'. This unique product, the 'Fierce 15 in Oncology Drug Pipeline Update' gathers the last five years (2010-2014) of Fierce 15 awards and ...  |  read more...
USD 4,485
1  2    4    6  7  8  9  10